產品分類
Product Category相關文章
Related Articles詳細介紹
商品屬性:
貨號 | 產品名稱 | 規(guī)格 |
GOY-01K0161 | 腫瘤抑制基因LATS1抗體 | 50ul |
GOY-01K0161 | 腫瘤抑制基因LATS1抗體 | 100ul |
GOY-01K0161 | 腫瘤抑制基因LATS1抗體 | 200ul |
英文名稱: LATS1
中文名稱: 腫瘤抑制基因LATS1抗體
別 名;Large tumor suppressor homolog 1; Serine
threonine protein kinase LATS1; WARTS; WARTS protein kinase; LATS1_HUMAN.
研究領域;腫瘤 免疫學 轉錄調節(jié)因子
抗體來源;Rabbit
克隆類型;Polyclonal
交叉反應;(predicted: Human, Mouse, Rat,
Chicken, Pig, Cow, Horse, Rabbit, )
產品應用;WB=1:500-2000
ELISA=1:5000-10000 IHC-P=1:100-500 (石蠟切片需做抗原修復)
not yet tested in
other applications.
optimal
dilutions/concentrations should be determined by the end user.
理論分子量;124kDa
細胞定位;細胞漿
性 狀;Liquid
濃 度;1mg/ml
免 疫 原;KLH conjugated synthetic
peptide derived from human LATS1: 821-950/1130
亞 型;IgG
純化方法;affinity purified by Protein A
保存條件;Shipped at 4℃. Store at -20 °C for one year. Avoid
repeated freeze/thaw cycles.
注意事項;This product as supplied is
intended for research use only, not for use in human, therapeutic or diagnostic
applications.
產品介紹 The protein encoded by this
gene is a putative serine/threonine kinase that localizes to the mitotic
apparatus and complexes with cell cycle controller CDC2 kinase in early
mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with
late prophase phosphorylation remaining through metaphase. The N-terminal
region of the protein binds CDC2 to form a complex showing reduced H1 histone
kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In
addition, the C-terminal kinase domain binds to its own N-terminal region,
suggesting potential negative regulation through interference with complex
formation via intramolecular binding. Biochemical and genetic data suggest a
role as a tumor suppressor. This is supported by studies in knockout mice
showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a
high sensitivity to carcinogenic treatments. [provided by RefSeq].
Function:
Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS1 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G1 tetraploidy checkpoint. Negatively regulates G2/M transition by down-regulating CDK1 kinase activity. Involved in the control of p53 expression. Affects cytokinesis by regulating actin polymerization through negative modulation of LIMK1. May also play a role in endocrine function.
實驗流程:
(1)特異性結合抗原:抗體本身不能直接溶解或殺傷帶有特異抗原的靶細胞,通常需要補體或吞噬細胞等共同發(fā)揮效應以清除病原微生物或導致病理損傷。然而,抗體可通過與病毒或毒素的特異性結合,直接發(fā)揮中和病毒的作用。
(2)活補體:IgM、IgG1、IgG2和IgG3可通過經典途徑激活補體,凝聚的IgA、IgG4和IgE可通過替代途徑激活補體。
(3)結合細胞:不同類別的免疫球蛋白,可結合不同種的細胞,參與免疫應答。
(4)可通過胎盤及粘膜:免疫球蛋白G(IgG)能通過胎盤進入胎兒血流中,使胎兒形成自然被動
免疫。免疫球蛋白A(IgA)可通過消化道及呼吸道粘膜,是粘膜局部抗感染免疫的主要因素。
(5)具有抗原性:抗體分子是一種蛋白質,也具有刺機體產生免疫應答的性能。不同的免疫球蛋白分子,各具有不同的抗原性。
(6)抗體對理化因子的抵抗力與一般球蛋白相同:不耐熱,60~70℃即被破壞。各種酶及能使蛋白質凝固變性的物質,均能破壞抗體的作用??贵w可被中性鹽類沉淀。在生產上??捎昧蛩徜@或硫酸鈉從免疫血清中沉淀出含有抗體的球蛋白,再經透析法將其純化。
抗體的制備過程:
1.免疫原:普通的大分子蛋白,通過分子克隆構建載體并在大腸桿菌中進行誘導表達獲得重組蛋白,純化鑒定后可直接作為免疫原;小分子蛋白或化合物等分子量小,需要偶聯載體對該分子進行改造才能使其成為具有免疫原性的抗原,常見偶聯載體如BSA、OVA、HAS等。
2. 免疫動物:常用于制備抗血清的動物有豚鼠、家兔、雞、大小鼠等,大量生產時需要用到狗、綿羊、山羊等。
3.免疫血清的收集:一般家兔、綿羊、山羊可采用靜動脈采血,家兔、豚鼠、大鼠、雞可采用心臟采血,家兔、山羊、綿羊可采用靜脈采血。
4. 腫瘤抑制基因LATS1抗體免疫血清的純化與鑒定:得到的抗血清需要進一步的純化,利用偶聯了抗原的親和柱進行層析,具有高效,特異性強,純度高的特定。接著要鑒定純化蛋白的含量、相對分子的質量、純度以及特異性。
5.免疫血清的保存:抗體一般比較穩(wěn)定,在-80℃ ~-20 ℃可以保存約5年而不會影響效價,而真空干燥保存時間可以更久。保存前需經除菌并添加防腐劑。
產品咨詢
電話
微信掃一掃